1. The Role of IDH Inhibitors in Hematologic Malignancies

3. AML What Is It and How Did It Get There?

4. Key Points From De Novo AML Genome Atlas-1

7. AML A Long List of Prognostic Features

9. Selected Targeted Therapy in AML

10. The Evolution of the Discovery of IDH Mutations in Cancer by Year

11. IDH Mutations Also Found in MDS, NHL and Range of Solid Tumors

12. IDH Mutations as a Target in AML

13. AG-221 Preclinical Data

14. Phase 1 Study of AG-120 in IDH1-Mutant Hematologic Malignancies

15. Phase 1 Study of AG-221 in IDH2-Mutant Hematologic Malignancies

16. Results of AG-221 Phase 1 Study

17. Responses With AG-221

18. Differentiation Effect in the Bone Marrow

20. IDH1 (AG-120) and IDH2 (AG-221) Inhibitors: Ongoing and Planned Studies

21. Abbreviations

22. Abbreviations (cont)

23. References

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)